TriSalus Life Sciences, Inc. (TLSI)

Market Cap	343.25M
Revenue (ttm)	40.21M
Net Income (ttm)	-70.83M
Shares Out	49.96M
EPS (ttm)	-2.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	176,520
Open	6.56
Previous Close	6.47
Day's Range	6.56 - 6.91
52-Week Range	3.42 - 6.91
Beta	0.47
Analysts	Strong Buy
Price Target	10.67 (+55.31%)
Earnings Date	Nov 13, 2025

About TLSI

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinic...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSI
• Website: https://trisaluslifesci.com

Financial Performance

In 2024, TriSalus Life Sciences's revenue was $29.43 million, an increase of 58.99% compared to the previous year's $18.51 million. Losses were -$33.23 million, -47.75% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for TLSI stock is "Strong Buy." The 12-month stock price target is $10.67, which is an increase of 55.31% from the latest price.

Price Target

$10.67

(55.31% upside)

Analyst Consensus: Strong Buy